The Digital Revolution: Unlocking The Power Of Data In Life Sciences
Rajnish Nath, President of Manufacturing, Automotive, Aerospace & Defense, and Life Sciences at Capgemini Americas.
The future of healthcare is here—and it's digital. From accelerating research to improving patient care, the integration of AI, data analytics and cutting-edge technologies is driving the industry into a new era where disruption is the norm.
However, while digital transformation has the potential to unlock unprecedented value, it's not simply a matter of upgrading technology. It requires a fundamental shift in mindset, with a strong focus on establishing a solid data foundation to drive meaningful progress in a world that is increasingly driven by automation, prediction, and personalization.
Data is the cornerstone of today's digital landscape, as it fuels these AI-enabled technologies to learn, adapt and deliver reliable results. As AI becomes more sophisticated, its effectiveness depends entirely on the quality and integrity of the data it's built on. Without strong data, even the most well-designed strategies and initiatives are built on unstable ground.
Throughout my 28-year tenure with Capgemini, I've served clients across all sectors and functions. A solid foundation of good data is particularly relevant in the life sciences industry, where advanced technology is bringing us into a new era of R&D and patient care. Our ability to understand how we leverage the power of data has never been more critical to achieving life-changing impact.
The life sciences industry generates vast amounts of data, but collecting it alone isn't enough. The real value lies in transforming raw data into actionable insights that drive improvements across the entire value chain—from enhancing patient outcomes to streamlining business operations. Yet, only 37% of life sciences organizations have standardized frameworks and tools in place to effectively collect, analyze and manage the full spectrum of data, including patient records, real-world outcomes and clinical trial results.
As the role of data in driving innovation becomes more apparent, many organizations are turning to strategic partnerships to streamline data management and deliver measurable business results. This shift comes at a time when the global life sciences analytics market is projected to nearly double—from $13.78 billion in 2025 to $27.75 billion in 2032—reflecting the growing demand for data-driven solutions. And while life sciences leads the charge, the value of quality data management is gaining importance across all industries, becoming the basis of digital transformation and a key factor in maintaining competitive advantage.
Partnerships that bring together functional innovation and precise data integration have the power to be truly transformative. This combination lays the groundwork for scalable, future-ready solutions designed to meet the evolving demands of a digital-first world.
After all, it's a saying we know well: Not all data is good data. In an age where information is everywhere, success depends not just on access but on the quality, accuracy and usability of the data at hand.
At this stage of mainstream digital transformation, quality data and advanced technologies like AI, machine learning and robotics are deeply interconnected—you simply can't have one without the other. The push to integrate advanced technologies, particularly within software-driven solutions, is motivated by the need to improve R&D efficiency, enhance market intelligence, streamline operations and deliver more personalized, effective patient care.
Despite the momentum, and with the global AI market in life sciences projected to reach $14.20 billion by 2034, many organizations still face considerable hurdles. Challenges related to strategy, governance, funding, talent, technology integration, data management and regulatory compliance often slow or complicate progress. In particular, the growing reliance on big data in drug discovery, development and clinical trials is forcing companies to reevaluate their capabilities.
Because of these challenges and the growing importance of data management and advanced technologies, here are several best practices that organizations can implement to successfully navigate this evolving landscape.
• Data-First Approach: Start AI initiatives by focusing on data quality and readiness to prevent cost overruns and delays and ensure AI readiness. Prioritizing data aligns transformation with business goals.
• Leverage Expertise: Utilize proven expertise and methodologies to handle complex data challenges. This includes employing a repeatable data migration approach that minimizes the risk of unsuccessful implementations and ensures high-quality data that aligns with business goals.
• Service Excellence: Engage in long-term guidance and services that extend beyond a project's onset. This includes consulting expertise, oversight, on-demand support and deep technical expertise to drive real business value continuously.
• Data Competency: Build the practice around the solutions to ensure the data initiatives are aligned with business goals, deliver measurable ROI and meet key performance indicators.
• Customer-Centric Focus: Prioritize the client's end-customer success by delivering exceptional value and aligning data outcomes with business outcomes. This approach minimizes risks and drives higher-value outcomes.
In today's increasingly digital landscape, validated processes are no longer optional—they're essential in a highly regulated environment where certified systems ensure compliance and data integrity.
Regulations such as medical device reporting (MDR) in the EU and unique device identification (UDI) in the U.S. have intensified the demand for accurate data collection and reporting, particularly as they relate to patient safety. At the same time, technological advancements are pushing organizations to continuously evolve their data models and adopt new systems to stay competitive. True effectiveness now lies in bridging regulatory compliance with business acumen, empowering organizations to make informed, scalable decisions backed by reliable data.
Looking ahead, data management practices must become more intentional. Where companies once stored every piece of data indefinitely, there's now a clear need to purge outdated or irrelevant information. Retaining only business-critical data helps minimize risk, enhance accuracy and build cleaner, more actionable datasets.
As digital transformation continues to reshape the life sciences industry, the ability to leverage quality data alongside advanced technologies will be the key to success. Organizations that build solid data foundations and integrate AI and machine learning effectively can drive faster innovation and better patient outcomes. With the right strategic approach, the future of healthcare is one where data is the driving force behind breakthrough treatments and operational excellence.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Stellantis Evaluates Maserati's Future, Including Potential Sale -- Reuters
Stellantis (STLA, Financials) is weighing a possible sale of its luxury brand Maserati as part of a broader strategic review, according to a Reuters report citing two unnamed sources familiar with the matter. Warning! GuruFocus has detected 11 Warning Signs with STLA. The discussions reportedly began before newly appointed CEO Antonio Filosa officially takes the helm. Maserati's future is under review as Stellantis navigates a shrinking U.S. market, Chinese competition, and steep tariffs imposed by President Donald Trump on foreign-made cars and parts. Despite the internal review, a Stellantis spokesperson told Reuters that Maserati is not for sale. McKinsey declined to comment. Maserati's sales fell by over 50% last year to 11,300 units, with no new models currently scheduled for launch. A new business plan is expected once Filosa begins his tenure. Stellantis' board remains split on the brand's futuresome directors reportedly view Maserati as a reputational asset, while others believe it lacks viability for a sustainable relaunch. Analysts say streamlining Stellantis' 14-brand portfolio could improve profit margins. The company's shares have lost roughly two-thirds of their value since March 2024. Chinese automakers such as Chery could emerge as potential buyers, echoing earlier moves like Geely's acquisition of Volvo or SAIC's purchase of MG. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
How Advisors Can Avoid Becoming Over-Reliant on AI
Apparently there's no AI in team. Artificial intelligence is being hailed as a key element of the fourth industrial revolution, and new tools are now assisting financial advisors with taking notes, drafting emails, and brainstorming thought leadership content. In fact, the vast majority of advisors said generative AI helped their practices, according to a survey earlier this year. But AI isn't a silver bullet. It lacks emotional intelligence and a human touch. Advisors risk damaging client relationships if they become too reliant on automation — even for routine tasks. 'AI is poor at empathy so far,' said Adrian Johnstone, CEO of the CRM platform Practifi. 'Advisors need to recognize where the personal connection is most powerful, and use AI to automate and alleviate the lesser functions.' READ ALSO: What the GENIUS Act Means for Stablecoins and Advisors and Why UBS Is the Only Wirehouse to Allow Podcasting Today, most advisors use AI to boost meeting efficiency and streamline workflows. Ideally, this frees up more time to spend with clients, but misusing these tools can backfire. 'The common refrain of disaffected clients is: 'I pay you to understand me, my goals, and my fears, not to outsource me to a machine,'' Johnstone said. Wealth management is built on bespoke service, but AI hasn't yet learned to fully adapt to individual client needs and goals. While tools that draft emails and website content are improving, the output still reads 'hollow and generic,' Johnstone warned. Use it or Lose it. Client-facing AI tools can be 'extremely risky' because they can't interpret emotional undertones of client's concerns, said Rafael Loureiro, CEO of an estate planning platform. Still, AI can be useful for quick, factual tasks. 'If it's midnight on a Sunday and a client asks, 'What was my marginal tax rate last year?' that's a perfect use case,' Loureiro said. 'It's not doing financial planning, but answering factual questions.' Everything in Moderation. This isn't the first time new tech or strategies meant to disrupt the wealth management industry have wound up causing trouble for advisors and their clients. Will Trout, director at Datos Insights, pointed to the 2008 financial crisis as a warning. 'Firms that over-relied on risk models without human oversight suffered catastrophic losses,' he told Advisor Upside. This post first appeared on The Daily Upside. To receive financial advisor news, market insights, and practice management essentials, subscribe to our free Advisor Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
